Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Research Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK) on Bullrun: market cap HKD 315.93B, P/E 36.6, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1276.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 315.93B
- P/E36.6
- Dividend yield0.5%
- Financial periodQ2 2026
- RevenueCNY 7.32B
- Net incomeCNY 2.18B
- Free cash flowCNY 327.87M
- Gross margin86.0%
Valuation Snapshot
latest market cap is HKD 315.93B; P/E is 36.6; dividend yield is 0.5%.
Peer valuation comparison
Latest P/E is 36.62x versus a Healthcare sector median of 21.8x (68.0% above).
Latest dividend yield is 0.46% versus a Healthcare sector median of 2.4% (80.8% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 315.93B | 36.6 | 0.4% | 0.23 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.23 HKD, yield 0.5%.
About Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
ETFs that hold Jiangsu Hengrui Pharmaceuticals Co.,Ltd
US-listed ETFs
Jiangsu Hengrui Pharmaceuticals Co.,Ltd is held by 20 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares China Large-Cap ETF (FXI) | 0.13% | 0.73% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | 0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Schwab Emerging Markets Equity ETF (SCHE) | 0.01% | 0.06% |
| Vanguard ESG International Stock ETF (VSGX) | <0.01% | 0.10% |
| JPMorgan Betabuilders Emerging Markets Equity ETF (BBEM) | 0.01% | 0.15% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Jiangsu Hengrui Pharmaceuticals Co.,Ltd's market cap?
Jiangsu Hengrui Pharmaceuticals Co.,Ltd's market capitalization is HKD 315.93B.
What is Jiangsu Hengrui Pharmaceuticals Co.,Ltd's P/E ratio?
Jiangsu Hengrui Pharmaceuticals Co.,Ltd's price-to-earnings (P/E) ratio is 36.6.
Does Jiangsu Hengrui Pharmaceuticals Co.,Ltd pay a dividend?
Jiangsu Hengrui Pharmaceuticals Co.,Ltd has a dividend yield of 0.5%.
What does Jiangsu Hengrui Pharmaceuticals Co.,Ltd do?
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.